High ERβ/HER oncogenic signaling defines lung tumors with an aggressive biology. We
previously showed that combining the anti-estrogen fulvestrant with the pan-HER inhibitor …

Immunotherapy is increasingly viewed as treatment of choice for lung cancer, however,
clinical responses to immune checkpoint blockade remain highly unpredictable and are …

Background Patient-derived xenograft (PDX) models are important tools in precision
medicine and for the development of targeted therapies to treat cancer patients. This study …

Kras-driven non–small-cell lung cancers (NSCLCs) are a leading cause of death with limited
therapeutic options. Many NSCLCs exhibit high levels of Ezh2, the enzymatic subunit of …

Immune checkpoint inhibitors against PD-1/PD-L1 yield improved survival rates of KRAS-
mutant NSCLC patients, who conferred a poor prognosis without effective targeted therapy …

As a critical signaling node, ERK1/2 are attractive drug targets, particularly in tumors driven
by activation of the MAPK pathway. Utility of targeting the MAPK pathway has been …

KRAS is one of the driver oncogenes in non-small-cell lung cancer (NSCLC) but remains
refractory to current modalities of targeted pathway inhibition, which include inhibiting …

Radiation therapy (RT), a critical modality in the treatment of lung cancer, induces direct
tumor cell death and augments tumor-specific immunity. However, despite initial tumor …

Non-small cell lung cancer (NSCLC) is a frequent type of cancer, which is mainly
characterized clinically by high aggressiveness and high mortality. KRAS oncoprotein is the …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …